MX2009004986A - Metodos de tratamiento de anemia hemolitica. - Google Patents

Metodos de tratamiento de anemia hemolitica.

Info

Publication number
MX2009004986A
MX2009004986A MX2009004986A MX2009004986A MX2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A
Authority
MX
Mexico
Prior art keywords
methods
hemolytic anemia
treating hemolytic
treating
complement
Prior art date
Application number
MX2009004986A
Other languages
English (en)
Spanish (es)
Inventor
Russell P Rother
Leonard Bell
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2009004986A publication Critical patent/MX2009004986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2009004986A 2006-11-08 2007-11-08 Metodos de tratamiento de anemia hemolitica. MX2009004986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/595,118 US20070116710A1 (en) 2004-02-03 2006-11-08 Methods of treating hemolytic anemia
PCT/US2007/023623 WO2008069889A2 (en) 2006-11-08 2007-11-08 Methods of treating hemolytic anemia

Publications (1)

Publication Number Publication Date
MX2009004986A true MX2009004986A (es) 2009-05-21

Family

ID=39326944

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004986A MX2009004986A (es) 2006-11-08 2007-11-08 Metodos de tratamiento de anemia hemolitica.

Country Status (10)

Country Link
US (1) US20070116710A1 (cg-RX-API-DMAC7.html)
EP (1) EP2089058A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010509338A (cg-RX-API-DMAC7.html)
KR (1) KR20090076960A (cg-RX-API-DMAC7.html)
AU (1) AU2007328435B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718830A2 (cg-RX-API-DMAC7.html)
CA (1) CA2669735A1 (cg-RX-API-DMAC7.html)
IL (1) IL198320A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009004986A (cg-RX-API-DMAC7.html)
WO (1) WO2008069889A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2073898A1 (en) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
EP2562256A3 (en) * 2007-09-24 2013-06-19 Noxxon Pharma AG C5a binding nucleic acids
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
JP2011510983A (ja) * 2008-01-29 2011-04-07 セルジーン コーポレイション Ｃｄ５９のレベルを調節するための、免疫調節化合物を使用する方法
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CA2780153A1 (en) 2009-11-09 2011-05-12 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
KR102034203B1 (ko) 2012-01-10 2019-10-18 아프타리온 바이오테크 아게 새로운 C5a 결합 핵산
JP6654137B2 (ja) * 2013-09-16 2020-02-26 チルドレンズ ホスピタル メディカル センター Ｈｓｃｔ関連血栓性微小血管症の治療のための組成物及び方法
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN113956354A (zh) 2015-01-22 2022-01-21 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
IT201600121482A1 (it) * 2016-11-30 2018-05-30 Univ Degli Studi Di Verona Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme
KR102365871B1 (ko) 2017-01-31 2022-02-21 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
US12037389B2 (en) 2017-12-01 2024-07-16 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
MY210523A (en) 2018-08-01 2025-09-29 Univ Osaka A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CR20220040A (es) 2019-07-31 2022-03-02 Hoffmann La Roche Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab
KR20240033090A (ko) 2019-07-31 2024-03-12 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
EP4135837A1 (en) 2020-04-16 2023-02-22 Assistance Publique, Hopitaux De Paris Methods for treating a complement mediated disorder caused by viruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ATE320450T1 (de) * 2000-12-05 2006-04-15 Alexion Pharma Inc Rationell entworfene antikörper
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease

Also Published As

Publication number Publication date
AU2007328435A1 (en) 2008-06-12
CA2669735A1 (en) 2008-06-12
JP2010509338A (ja) 2010-03-25
IL198320A0 (en) 2011-08-01
US20070116710A1 (en) 2007-05-24
EP2089058A2 (en) 2009-08-19
AU2007328435B2 (en) 2013-03-07
KR20090076960A (ko) 2009-07-13
BRPI0718830A2 (pt) 2014-02-04
WO2008069889A3 (en) 2008-08-07
WO2008069889A2 (en) 2008-06-12
WO2008069889A9 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
WO2005074607A3 (en) Method of treating hemolytic disease
NO20083153L (no) Kjemiske forbindelser
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EA200802428A1 (ru) Комбинации агентов для биологической борьбы и нематоцидов, входящих в покрытие семян
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
SG170813A1 (en) New compounds
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
MX2008007307A (es) Granulos/capsulas modificados que contienen ingrediente activo.
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
TW200716624A (en) Compounds for modulating TRPV3 function
UA90209C2 (ru) Фунгицидная композиция, способ борьбы с заболеваниями полезных растений и способ защиты товаров
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
TW200714283A (en) Method and composition for treating peripheral vascular diseases
WO2007095638A3 (en) Boron-containing small molecules as anti-inflammatory agents
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
EP2425849A3 (en) Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
EA200601766A1 (ru) Производные имидазола
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal